Abstract
Medullary thyroid carcinoma (MTC) comprises 5–10% of all thyroid malignancies and occurs sporadically in 75% of cases, while the remainder develop in association with multiple endocrine neoplasia (MEN) 2A, MEN2B, or familial MTC (FMTC). The MEN2 syndromes, which have autosomal dominant patterns of inheritance, occur as the result of germline mutations in the RET proto-oncogene (10q 11.2). Guidelines for age-stratified prophylactic thyroidectomies in MEN2A, MEN2B, and FMTC are now based on the results of mutational analyses. The tumors exhibit a remarkably wide spectrum of histological appearances and may mimic every type of thyroid malignancy. A small proportion of the cases represent mixed follicular and C cell neoplasms. The heritable tumors are preceded in their development by phases of C cell hyperplasia although there is a growing body of data to support the view that the proliferating C cells represent preinvasive malignancies (carcinomas in situ). C cell hyperplasia (CCH) also occurs in patients with hypercalcemia, hypergastrinemia, Hashimoto's disease, and in the immediate vicinity of follicular cell neoplasms (peritumoral CCH). The latter types of hyperplasia have been classified as physiological or secondary CCH as compared to the C cell proliferative changes in the MEN2 syndromes. In contrast to physiological hyperplasia in which C cells most often appear normal cytologically, the C cells in MEN2 syndromes are frequently dysplastic. However, these distinctions may not always be apparent in individual cases, including some normal glands, which may demonstrate considerable variations in C cell distribution and morphology.
Keywords
- Medullary Thyroid Carcinoma
- Follicular Cell
- Cell Hyperplasia
- Medullary Carcinoma
- Nodular Thyroid Disease
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Rosai J, Carcangiu MI, DeLellis RA. (1992) Tumors of the Thyroid Gland Atlas of tumor Pathology. Washington DC: Armed Forces Institute of Pathology 207–258
Matias-Guiu X, DeLellis RA, Moley JF et al. (2004) Medullary thyroid carcinoma. In: R.A. DeLellis, R.V. Lloyd, P.U. Heitz and C. Eng (Ed.) Pathology and Genetics of Tumours of Endocrine Organs. WHO Classification of Tumours (pp. 86–91) IARC Press, Lyon
Horn RC, (1951) Carcinoma of the thyroid. Description of a distinctive morphological variant and report of seven cases. Cancer 4:697–707
Hazard JB, Hawke WA, Crile G (1959) Medullary (solid) carcinoma of the thyroid: A clinicopathological entity. J Clin Endocrinol Met 19:152–161
Williams ED (1966) Histogenesis of medullary carcinoma of the thyroid. J Clin Pathol 19:114–118
Bussolati G, Pearse AGE (1967) Immunofluorescent localization of calcitonin in the ‘C’-cells of the dog and pig thyroid. J Endocrinol 37: 205–209
Tashjian AH, Melvin EW (1968) Medullary carcinoma of the thyroid gland. Studies of thyrocalcitonin in plasma and tumor extracts. N Engl J Med 279:279–283
Melvin KE, Miller HH, Tashjian AH Jr. (1971) Early diagnosis of medullary carcinoma of the thyroid means of calcitonin assay. N Engl J Med 285:1115–1120
DeLellis RA, Wolfe HJ (1981) The pathology of human calcitonin (C)-cell. A Rev Pathol Annu 16:25–52
Pacini F, Fontanelli M, Fugazzola L et al. (1994) Routine measurement of serum calcitonin in nodular thyroid disease allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 78:826–829
DeLellis RA (1995) Multiple endocrine neoplasia syndromes revisited. Clinical, morphological and molecular features. Lab Invest 72:494–505
Lips CMJ, Vasen HFA, Lamers CBHW (1988) Multiple endocrine neoplasia syndromes. CRC Crit Rev. Oncol Hematol 2:117–184
Gimm O, Morrison CD, Suster S et al. (2004) Multiple endocrine neoplasia type 2. In: R.A. DeLellis, R.V. Lloyd, P.U. Heitz and C. Eng (Ed.) Pathology and Genetics of Tumours of Endocrine Organs. WHO Classification of Tumours (pp. 211–217) IARC Press, Lyon
Kebebew E, Ituarte PHG, Siperstein AE et al. (2000) Medullary thyroid carcinoma. Clinical characteristics; treatment, prognostic factors and a comparison of staging systems. Cancer 88:1139–1148
Barbosa SL-S, Rodien P, Leboulleux S et al. (2005) Ectopic adrenocorticotropic hormone-syndrome in medullary carcinoma of the thyroid: a retrospective analysis and review of the literature. Thyroid 15:618–623
Gagel RF, Tashjian AH, Jr., Cummings T et al. (1988) The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a: An 18 year experience. N Engl J Med 318:478–484
Verga U, Fugazzola L, Cambiaghi S et al. (2005) Frequent association between MEN2A and cutaneous lichen amyloidosis. Clin Endocrinol (Oxf) 59:156–161
Verdy M, Weber AM, Roy CC et al. (1982) Hirschsprung's disease in a family with multiple endocrine neoplasia type 2. J Pediatr Gastroenterol Nutr 1:603–607
DeLellis RA, Wolfe HJ, Gagel RF et al. (1976) Adrenal medullary hyperplasia: A morphometric analysis in patients with familial medullary thyroid carcinoma. Am J Pathol l83: 177–196
Carney JA, Sizemore GW, Tyce, GM (1975) Bilateral adrenal medullary hyperplasia in multiple endocrine neoplasia type 2: the precursor of bilateral pheochromocytoma. Mayo Clin Proc 50:3–10
Carney JA, Sizemore GW, Hayles AB (1978) Multiple endocrine neoplasia type 2B. Pathobiol Ann 8:105–153
Farndon JR, Leight GS, Dilley WG et al. (1986) Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 73 (4):278–281
Elisei R, Romei C, Cosci B et al. (2007) RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 92:4725–4729
Mizukami Y, Kurumaya H, Nonomura A et al. (1992) Sporadic medullary microcarcinoma of the thyroid. Histopathology 21:373–377
Zaatari GS, Saigo PC, Huvos AG (1983) Mucin production in medullary carcinoma of the thyroid. Arch Pathol Lab Med 107:70–74
Sletton K, Westermark P, Natwig JB (1976) Characterization of amyloid fibril proteins from medullary carcinoma of the thyroid. J Exp Med 143:993–998
Khurana R, Agarwal A, Bajpai VK et al. (2004) Unraveling the amyloid associated with human medullary carcinoma. Endocrinol 154:5465–5470
Kini S (2008) Thyroid Cytopathology: An Atlas and Text. Philadelphia: Lippencott Williams and Wilkins
DeLellis RA, Nummemacher G, Wolfe HJ. (1977) C-cell hyperplasia: An ultrastructural analysis. Lab Invest 36:237–248
Kaufmann O, Dietel M (2000) Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathol 36:415–420
Bejarano PA, Nikiforov YE, Swenson ES, Biddinger PW (2000) Thyroid transcription factor-1, thyroglobulin, cytokeratin 7 and cytokeratin 20 in thyroid neoplasms. Appl Immunohistochem Mol Morphol 8:189–194
Kimura N, Nakazato Y, Nagura H, Sasano N (1990) Expression of intermediate filaments in neuroendocrine tumors. Arch Pathol Lab Med 114:506–510
DeLellis RA (1993) The pathology of medullary thyroid carcinoma and its precursors. In: LiVolsi, VA, DeLellis, RA (ed) Pathology of the Parathyroid and Thyroid Glands, pp. 77–102. Baltimore Williams and Wilkins
Holm R, Sobrinho-Simoes M, Nesland JM Fould VE, Johannessen JV (1985) Medullary carcinoma of the thyroid gland: and immunocytochemical study. Ultrastruct Pathol 8:25–41
Portela-Gomes GM, Luckinius GM, Grimeluis L (2000) synaptic vesicle protein 2, a new neuroendocrine cell marker. Am J Pathol 157:1299–1309
Schmid KW, Fisher-Colbrie R, Hagn C, Jasani B, Williams, Ed, Winkler H (1987) Chromogranin A and B and secretogranin II in medullary carcinomas of the thyroid. Am J Surg Pathol 11:551–556
Katsetos CD, Jami MM, Krishna L, Jackson R, Patchefsky AS, Cooper HS (1994) Novel immunohistochemical localization of 28,000 molecular weight (Mr) calcium binding protein (Calbindin-D28 k) in enterochromaffin cells of the human appendix and neuroendocrine tumors (carcinoids and small cell carcinomas) of the midgut and foregut. Arch Pathol Lab Med 11:633–639
Komminoth P, Roth J, Saremaslani P, Matias-Guiu T, Wolfe HF, Heitz PU (1994) Polysialic acid of the neural cell adhesion molecule in the human thyroid: a marker for medullary thyroid carcinoma and primary C-cell hyperplasia. An immumohistochemical study of 70 thyroid lesions. Am J Surg Pathol 18:399–411
Saad MF, Ordonez NG, Guido JJ, Samaan Na (1984) the prognostic value of calcitonin immunostaining in medullary carcinoma of the thyroid. J Clin Endocrinol Metab 59:850–856
Sikri KL, Varndell IM, Hamid QA et al. (1985) Medullary carcinoma of the thyroid. An immunocytochemical and histochemical study of 25 cases using 8 separate markers. Cancer 56:2481–2491
Steenbergh PH, Heppner JW, Zandberg J et al. (1984) Calcitonin gene related peptide coding sequence is conserved in the human genome and is expressed in medullary thyroid carcinoma. J Clin Endocrinol Metab 5:358–360
Zajac JD, Penschow J, Mason T et al. (1986) Identification of calcitonin and calcitonin gene-related peptide messenger RNA in medullary thyroid carcinoma by hybridization histochemistry. J Clin Endocrinol Metab 62:1037–1043
Scopsi L Ferrari C, Pilotti S et al. (1990) Immunocytochemical localization and identification of prosomatostatin gene products in medullary carcinoma of human thyroid gland. Hm Pathol 21:820–830
Sunday ME, Wolfe HJ, Roos BA, Chin WW, Spindel ER (1988) Gastrin releasing peptide gene expression in developing, hyperplastic and neoplastic thyroid C-cell. Endocrinol 122:1551–1558
Williams ED, Morales AM, Horn RC (1968) Thyroid carcinoma and Cushing's syndrome. A report of two cases with review of the common features of the non-endocrine tumours associated with Cushing's syndrome. J Clin Pathol 21:129–135
Roth KA, Bensch KG, Hoffman AR (1987) Characterization of opioid peptides in human thyroid medullary carcinoma. Cancer 59:850–856
Birkenhäger JC, Upton GV, Seldenrath HJ, Krieger DT, Tashjian AH Jr. (1976) Medullary thyroid carcinoma: ectoic production of peptides with ACTH-like, corticotropin-releasing factor-like and prolactin production—stimulating activities. Acta Endocrinol (Copenh) 83:280–292
Uribe M, Fenoglio-Preiser CN, Grimes M, Feind C. (1985) Medullary carcinoma of the thyroid gland. Clinical, pathological, and immunohistochemical features with review of the literature. Am J Surg Pathol 9:577–594
Faggiano A, Talbot M, Lacroix L et al. (2002) Differential expression of galectin-3 in medullary thyroid carcinoma and C-cell hyperplasia. Clin Endocrinol 57:813–819
DeLellis RA, Rule AH, Spiler I, Nathanson L, Tashjian AH, Jr., Wolfe HJ (1978) Calcitonin and carcinoembryonic antigen as tumor markers in medullary thyroid carcinoma. Am J Clin Pathol 70:587–594
Schroder S, Klöppel G (1987) Carcinoembryonic antigen and non-specific cross-reacting antigen in thyroid cancer. An immunocytochemical study using polyclonal and monoclonal antibodies. Am J Surg Pathol 11:100–108
Mendelsohn G, Wells SA, Baylin SB (1984) Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized and virulent disseminated stages of disease. Cancer 54:657–662
Kakudo K, Miyauchi A, Yakai SI et al. (1979) C-cell carcinoma of the thyroid, papillary type. Acta Pathol (Jpn) 29:663–659
Harach HR, Williams ED (1983) Glandular (tubular and follicular) variants of medullary carcinoma of the thyroid. Histopathology 7:83–97
Harach HR, Bergholm U (1992) Small cell variant of medullary carcinoma of the thyroid with neuroblastoma-like features. Histopathol 21:378–380
Eusebi V, Damiani S, Riva C, Lloyd RV, Capella C (1990) Calcitonin free oat cell carcinoma of the thyroid gland. Virchows Arch [A] 417:267–271
Mendelsohn G, Baylin SB, Bigner SH et al. (1980) Anaplastic variants of medullary thyroid carcinoma: a light microscopic and immunohistochemical study. Am J Surg Pathol 4:333–341
Landon G, Ordóñex NG (1985) Clear cell variant of medullary carcinoma of the thyroid. Hum Pathol 16:844–847
Marcus JN, Dise CA, LiVolsi VA (1982) Melanin production in a medullary thyroid carcinoma. Cancer 49:2518–2526
Beerman H, Rigaud C, Bogomeletz WV, Hollander H, Veldhuizen H (1990) Melanin production in black medullary thyroid cancer (MTC). Histopathology 16:227–234
Dominguez-Malagon H, Delgardo-Chavez R, Torres-Najera M, Gould E, Albores-Saavedra J (1989) Oxyphil and squamous variants of medullary thyroid carcinoma. Cancer 63:1183–1188
Golough R, Us-Krasovec M, Auersperg M, Jancar J, Bondi A, Eusebi V (1985) Amphicrine-composite calcitonin and mucin producing carcinoma of the thyroid. Ultrastruct Pathol 8:197–206
Huss LJ, Mendlesohn G (1990) Medullary carcinoma of the thyroid gland: an encapsulated variant resembling the hyalinizing trabecular (paraganglioma-like) adenoma of thyroid. Mod Pathol 3:581–585
Laforga JB, Aranda FI (2007) Pseudoangiosarcomatous features in medullary thyroid carcinoma spindle cell variant. Report of a case studied by FNA and immunohistochemistry. Diagn Cytopathol 34:424–428
Beskid M, Lorenc R, Rôsciszewska A (1971) C-cell thyroid adenoma in man. J Pathol 103:3343–346
Kodama T, Okamoto T, Fujjimoto Y et al. (1988) C-cell adenoma in the thyroid: a rare but distinct clinical entity. Surgery 104:997–1003
Mendelsohn G, Oertel JE (1981) Encapsulated medullary thyroid carcinoma [Abstract]. Lab Invest 44:43A
Matias-Guiu X, LaGuette J, Puras-Gil AM, Rosai, J (1997) Metastatic neuroendocrine tumors to the thyroid mimicking medullary carcinoma: a pathological and immunohistochemical study of six cases. Am J Surg Pathol 21:754–762
Shikama Y, Osawa T, Yagihashis N et al. (2003) Neuroendocrine differentiation in hyalinizing trabecular tumors of the thyroid. Virchows Arch 443:792–796
Wolfe HJ, Melvin KE, Cervi-Skinner SJ et al. (1973) C-cell hyperplasia preceding medullary thyroid carcinoma. N Engl J Med 289: 437–441
Wells SA, Ontjes DA, Cooper CW et al. (1975) The early diagnosis of medullary carcinoma of the thyroid gland in patients with multiple endocrine neoplasia type II. Ann Surg 182:362–370
McDermott MB, Swanson PE, Wick MR (1995) Immunostains for collagen type IV discriminate between C-cell hyperplasia and microscopic medullary carcinoma in multiple endocrine neoplasia, type 2A. Hum Pathol 26:1308–1312
Albores-Saavedra J, Monforte H, Nadji M, Morales AR (1988) C-cell hyperplasia in thyroid tissue adjacent to follicular cell tumors. Hum Pathol 19:795–799
Guyetant S, Rousselet MC, Durigon M et al. (1997) Sex related C-cell hyperplasia in the normal human thyroid: a quantitative autopsy study. J Clin Endocrinol Metab 82:42–47
Perry A, Molberg K, Albores-Saavedra J (1996) Physiologic versus neoplastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities. Cancer 77:750–756
Carney JA, Sizemore GW, Hales AB (1978) Multiple endocrine neoplasia, type 2B. Pathobiol Annu 8:105–153
Diaz-Cano S, DeMiguel M, Blanes A et al. (2001) Germline RET634 mutation positive MEN2A related C-cell hyperplasias have genetic features consistent with intraepithelial neoplasias. J Clin Endocrinol Metab 86:3948–3951
Kaserer K, Scheuba C, Neuhold N et al. (1998) C-cell hyperplasia and medullary thyroid carcinoma in patients routinely screened for serum calcitonin. Am J Surg Pathol 22:722–728
Kaserer K, Scheuba C, Neuhold N et al. (2001) sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients. Am J Surg Pathol 25:1245–1251
Mears L, Diaz-Cano S (2003) Difference between familial and sporadic medullary thyroid carcinomas (Letter). Am J Surg Pathol 27:266–267
Mathew CG, Chin KS, Easton DF et al. (1987) A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328:527–528
Simpson NE, Kidd KK, Goodfellow PJ et al. (1987) Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 328:528–530
Ponder BA, Coffe R, Gagel RF et al. (1988) Risk estimation and screening of families of patients with medullary thyroid carcinoma. Lancet 1:397–401
Sobol H, Narod SA, Nakamura Y et al. (1989) Screening for multiple endocrine neoplasia type 2A with DNA polymorphism analysis. N Engl J Med 321:996–1001
Gardner E, Papi L, Easton DF et al. (1993) Genetic linkage studies map the multiple endocrine neoplasia type 2 loci to a small interval of chromosome 10q 11.2 Hum Mol Gent 2:241–246
Lairmore TC, Dou S, Howe JR et al. (1993) A1.5 megabase yeast artificial chromosome contig from human chromosome 10q 11.2 connecting 3 genetic loci (RET,D10S94, and D10S102) closely linked to the MEN2A locus. Proc Nat'l Acad Sci USA 90: 492–496
Mole SE, Mulligan LM, Healey CS et al. (1993) Localization of the gene for localization of the gene for multiple endocrine neoplasia type 2A to a 480 kb region in chromosome band 10q 11.2. Hum Mol Genet 2:247–252
Mulligan LM, Kwok JBJ, Healey CS et al. (1993) Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A Nature 363:458–460
Donis-Keller H, Dou S, Chi D et al. (1993) Mutations in the RET proto-oncogene are associated with MEN2A and FMTC. Hum Mol Genet 2:851–856
Mulligan LM, Eng C, Healey CS et al. (1994) Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN2A and FMTC. Nature Genet 6:70–74
Hofstra RM, Landsvater RM, Ceccherini I et al. (1994) A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375–376
Eng C, Smith DP, Mulligan LM et al. (1994) Point mutations within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumors. Hum Mol Genet 3:237–241
Carlson KM, Dou S, Chi D et al. (1994) single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 91:1579–1583
Eng C, Clayton D, Schuffenecker I et al. (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575–1579
Eng C (1999) RET proto-oncogene in the development of human cancer. J Clin Oncol 17:380–393
Hoff AO, Cote GJ, Gagel RF (2000) Multiple endocrine neoplasias. Annu Rev Physiol 62:377–341
Takahashi M, Buma Y, Iwamoto T (1988) Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 3:571–578
Pasini B, Hofstra RM, Yin L et al. (1995) The physical map of the RET proto-oncogene. Oncogene 11:1737–1743
Pachnis V, Mankoo B, Costantiri F (1993) Expression of the C-ret proto-oncogene during mouse embryogenesis. Development 119:1005–1017
Schuchardt A, D'Agati V, Larsson-Bloomberg L, Costantini F, Pachnis V (1994) Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor ret. Nature 367:380–383
Lai AZ, Gujral TS, Mulligan LM (2007) RET signalling in endocrine tumors: delving deeper into molecular mechanisms. Endocrin Pathol 18:57–67
Santoro, M, Carlomagno F, Romano A et al. (1995) Activation of RET as a dominant transforming by germline mutations of MEN2A and MEN2B. Science 267:381–383
Iwashita T, Asai N, Murakami H et al. (1976) Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutations. Oncogene 12:481–487
Gimm O, Marsh DJ Andrew SD et al. (1997) Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 81:3902–3904
Smith DP, Houghton C, Ponder BA (1997) Germline mutation of RET codon 883 in two cases of de novo MEN2B. Oncogene 15:1213–1217
Kawai K, Iwashita T, Murakami H et al. (2000) Tissue specific carcinogenesis in neoplasia type 2A mutation. Cancer Res 60:5254–5260
Wohllk N, Cote GJ, Bugalho MM et al. (1996) Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81:3740–3745
Zedenius J, Wallin G, Hamberger B et al. (1994) Somatic and MEN2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTCs. Hum Mol Genet 3:1259–1262
Eng C, Mulligan LM, Healey CS et al. (1996) Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 56:2167–2170
Marsh DJ, Learoyd DL, Andrew SD et al. (1996) Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol 44:249–257
Saggiorato E, Rapa I, Garino F et al. (2007) Absence of RET gene point mutation in sporadic C-cell hyperplasia. J Mol Diagn 9:214–219
Eng C, Crossey PA, Mulligan LM et al. (1995) Mutations of the RET proto-oncogene and von Hippel Lindau disease tumour suppressor gene in sporadic and syndromic pheochromocytoma. J Med Genet 32:934–937
Lindor LM, Honchel R, Khosla S et al. (1995) Mutations in the RET proto-oncogene in sporadic pheochromocytomas. J Clin Endocrinol Met 80:627–629
Beldjord B, Desclaux-Arranond F, Raffin-Samson M et al. (1995) The RET proto-oncogene in sporadic pheochromocytomas. Frequent MEN2-like mutations and new molecular defects. J Clin Endocrinol Metab 80:2063–2068
Padberg BC,Schroder S, Jochum W et al. (1995) Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland. Am J Pathol 147:1600–1607
Komminoth P, Roth J, Mulletta-Feurer S et al. (1996) RET proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab 81:2041–2046
Eng C, Mulligan LM, Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndrome, related sporadic tumours and Hirschsprung disease. Hum Mut 9:97–109
Peacock ML, Borst MJ, Sweet JD, Decker RA (1996) Detection of RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma by denaturing gel electrophoresis. Hum Mut 7:100–104
Wohllk N, Cote GJ, Evans DB et al. (1996) Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Endocrinol Metab Clinics North Am 25:1–25
Wells SA, Chi DD, Toshima K et al. (1994) Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 220:237–250
Lips CJ, Landsvater RM, Hoppener JW et al. (1994) Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 331:828–835
Dralle H, Gimm O, simon D et al. (1998) Prophylactic thyroidectomy in 75 children and adolescents with hereditary mudullary thyroid carcinoma: German and Austrian experience. World J Surg 22 (7):744–751
Offit K, Biesecker BB, Burt RW et al. (1996) Statement of the American Society of Oncology: Genetic Testing for Cancer Susceptibility. J Clin Oncol 14:1730–1736
Fialkowski EA, Moley JF (2006) Current approaches to medullary thyroid carcinoma, sporadic and familial. J Surg Oncol 94:737–747
Moley JF, Fialkowski EA (2007) Evidence based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 31:946–956
Modigliani E, Cohen R, Campos JM et al. (1998)Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 819 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin Endocrinol (Oxf) 48:265–273
Vezzosi D, Bennet A, Caron P (2007) Recent advances in treatment of medullary thyroid carcinoma. Ann Endocrinol (Paris) 68:147–153
Leboulleux S, Travagli JP, Caillou B et al. (2002) Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome. Influence of the stage on the clinical course. Cancer 94:44–50
Schröder S, Böcker w, Baisch H et al. (1998) Prognostic factors in medullary thyroid carcinoma. Survival in relation to age, sex, stage, histology, immunohistochemistry and DNA content. Cancer 61:806–816
Koporek O, Scheuba C, Cherenko M, et al. (2008) Desmoplasia in medullary thyroid carcinoma: a reliable indicator of metastatic potential. Histopathol 52:623–630
Barbet J, Campion L, Kraeber-Bodere F, Chatal JF (2005) Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077–6084
Elisei R, Cosci B, Romei C et al. (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid carcinoma: a 10-year follow-up study. J Clin Endocrinol Metab 93:682–687
Hales, M, Rosenau, W, Okerlund, MD, Galante, M. (1982) Carcinoma of the thyroid with a mixed medullary and follicular pattern: morphological, immunohistochemical and clinical laboratory studies. Cancer 50:1352–1359
Pfaltz, M, Hedinger, Chr. E, Muhlethales, JP. (1983) Mixed medullary and follicular carcinoma of the thyroid. Virchows Arch [Pathol. Anat] 400:53–59
Ljungberg, O, Ericsson, U-B, Bondeson, L, Thorell, J. (1984) A compound follicular-parafollicular cell carcinoma of the thyroid: A new tumor entity? Cancer 52:1053–1061
Ljungberg O. Bondeson L. Bondeson AG (1984) A-G. Differentiated thyroid carcinoma, intermediate type: a new tumor entity with features of follicular and parafollicular cell carcinoma. Hum Pathol 15:218–228
Holm R, Sobrinho-Simoes M, Nesland JM, Sambade C, Johannessen JV (1987) Medullary thyroid carcinoma with thyroglobulin immunoreactivity. A special entity? Lab Invest 57:258–268
LiVolsi, VA. (1987) Mixed thyroid carcinoma: A real entity? Lab Invest 57:237–239
Albores-Saavedra J, de la Mora TG, de la Torra-Rendon F, Gould E. (1990) Mixed medullary-papillary carcinoma of the thyroid: A previously unrecognized variant of thyroid carcinoma. Hum Pathol 21:1151–1155
Mizukami Y, Michigishi T, Nonomura A, et al. (1993) Mixed medullary-follicular carcinoma of the thyroid occurring in familial form. Histopathol 22:284–287
Matias-Guiu X, Caixas A, Costa I, Cabezas R, Prat J. (1994) Compound medullary-papillary carcinoma of the thyroid: true mixed versus collision tumour. Histopathol 25:183–185
Lax SF, Beham A, Kronberger-Schönecker D, Langsteger W, Denk H. (1994) Coexistence of papillary and medullary carcinoma of the thyroid gland-mixed or collision tumors? Clinicopathological analysis of three cases. Virchows Archiv 424:441–447
Kobayashi K, Teramoto S, Maeta H, Ishiguro S, Mori T, Horie Y. (1995) Simultaneous occurrence of medullary carcinoma and papillary carcinoma of the thyroid. J Surg Onc 59:276–279
Mizukami Y, Nonomura A, Michigishi T, Noguchi M, Ishizaki T. (1996) Mixed medullary-follicular carcinoma of the thyroid gland: a clinicopathologic variant of medullary thyroid carcinoma. Mod Pathol 9:631–635
Papotti M, Negro F, Carney JA, Bussolati G, Lloyd RV. (1997) Mixed medullary-follicular carcinoma of the thyroid. A morphological, immunohistochemical and in situ hybridization analysis of 11 cases. Virchows Arch 430:397–405
Matias-Guiu X. (1999) Mixed medullary and follicular carcinoma of the thyroid. On the search for its histogenesis. Am J Pathol 155:1413–1418
Volante, M, Papotti, M, Roth, J. et al. (1999) Mixed medullary-follicular thyroid carcinoma. Molecular evidence for a dual origin of tumor components. Am J Pathol 155:1499–1509
Pappoti M, Volante M, Komminoth P, Sobrinho-Simoes M, Bussolati G. (2000) Thyroid carcinomas with mixed follicular and C-cell differentiation patterns. Semin Diagn Pathol 17:109–119
Katoh R, Jasani B, Williams ED. (1989) Hyalinizing trabecular adenomas of the thyroid: A report of three cases with immunohistochemical and ultrastructural studies. Histopathol 15:211–224.
Carcangiu ML, Zampi G, Rosai J (1984) Poorly differentiated (“insular”) thyroid carcinoma. A reinterpretation of Langhans “wuchernde struma”. Am J Surg Pathol 8:655–668
Sobrinho-Simoes M. (1996) Poorly differentiated carcinomas of the thyroid. Endocrine Pathol 7:99–102
Papotti M, Bussolati G, Kommoth P, et al. (2004) Mixed medullary and follicular cell carcinoma. In R.A. DeLellis, R.V. Lloyd, P.U. Heitz, C Eng (ed). Pathology and Genetics of Tumours of Endocrine Organs. WHO Classification of Tumours, pp. 92–92. Lyon: IARC Press
Mellilo RM, Cirafici AM, DeFalco V et al. (2004) The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Am J Pathol 165:511–521
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
DeLellis, R.A. (2009). Tumors of the Thyroid Gland (C-Cells). In: Khan, A. (eds) Surgical Pathology of Endocrine and Neuroendocrine Tumors. Current Clinical Pathology. Humana Press. https://doi.org/10.1007/978-1-60327-396-1_6
Download citation
DOI: https://doi.org/10.1007/978-1-60327-396-1_6
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-395-4
Online ISBN: 978-1-60327-396-1
eBook Packages: MedicineMedicine (R0)